<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203642</url>
  </required_header>
  <id_info>
    <org_study_id>KD019-211</org_study_id>
    <nct_id>NCT03203642</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD</brief_title>
  <official_title>A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to compare and evaluate safety and efficacy of tesevatinib 50mg
      versus placebo in patients with ADPKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety and efficacy of 50mg tesevatinib in comparison to placebo in patients with autosomal
      dominant polycystic kidney disease (ADPKD) will be assessed.

      The primary purpose of this study is focused on evaluating the change from baseline in
      height-adjusted total kidney volume (htTKV) as measured by magnetic resonance imaging (MRI)
      at Months 12, 18, and 24 in patients with ADPKD treated with tesevatinib or placebo.

      If eligible for the study participation, subjects will be randomly assigned to either
      investigational treatment group or placebo group. Treatment group will receive 50mg
      tesevatinib once daily for 24 months and control group will receive the placebo once daily
      for 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Anticipated">August 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of height-adjusted total kidney volume (htTKV) in participants with ADPKD treated with tesevatinib 50mg or placebo.</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline of the htTKV will be measured by magnetic resonance imaging (MRI) at Months: 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of height-adjusted total kidney volume (htTKV) in participants with ADPKD treated with tesevatinib 50mg or placebo.</measure>
    <time_frame>18 month</time_frame>
    <description>Change from baseline of the htTKV will be measured by magnetic resonance imaging (MRI) at Months: 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of height-adjusted total kidney volume (htTKV) in participants with ADPKD treated with tesevatinib 50mg or placebo.</measure>
    <time_frame>24 month</time_frame>
    <description>Change from baseline of the htTKV will be measured by magnetic resonance imaging (MRI) at Months: 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of tesevatinib 50mg administered once daily in patients with ADPKD measured as incidence of treatment-emergent adverse events.</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of adverse events occurring at the duration of the study will be identified with the following assessments: 12-lead ECGs, ocular evaluations, clinical laboratory tests, echocardiograms, and physical exams.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney</condition>
  <condition>ADPKD</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg tesevatinib administered once daily for up to 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered once daily for up to 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesevatinib</intervention_name>
    <description>A once daily dose of tesevatinib 50 mg in a round tablet form of white to off-white color.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>KD019</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A once daily dose of matching placebo.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADPKD diagnosis based on Ravine's criteria

          -  Cysts of at least 1 cm

          -  eGFR ≥ 30 mL/min/1.73 m2 and ≤ 80 mL/min/1.73 m2, using the Modification of Diet in
             Renal Disease-4 variable formula

          -  htTKV ≥ 900 mL

          -  The subject has the following laboratory values:

        Platelets &gt; lower limit of normal (LLN) Hemoglobin &gt; 9 g/dL Total bilirubin ≤ 1.5 mg/dL
        Aspartate aminotransferase (AST) &lt; 2.5 × upper limit of normal (ULN) Alanine
        aminotransferase (ALT) &lt; 2.5 × ULN Prothrombin time/partial thromboplastin time ≤ 1.5 × ULN
        Serum potassium levels within normal limits Serum magnesium levels within normal limits
        Albumin ≥ LLN Amylase within normal limits Lipase within normal limits Prothrombin time
        (PT) and partial thromboplastin time (PTT) ≤ 1.5 × ULN International normalized ratio (INR)
        ≤ 1.5, except those subjects taking warfarin who must have INR ≤ 3

          -  Female subjects of childbearing potential with negative pregnancy test at screening

          -  If sexually active, the subject agrees to use 2 accepted methods of contraception
             during the course of the study and for 6 months after their last dose of study drug

        Exclusion Criteria:

          -  Previous nephrectomy

          -  Kidney transplant

          -  Tuberous sclerosis

          -  Hippel-Lindau disease

          -  Acquired cystic disease

          -  Congenital absence of 1 kidney and/or need for dialysis or transplantation in the
             foreseeable future

          -  Moderate hematuria

          -  Uncontrolled hypertension

          -  Presence of renal or hepatic calculi (stones) causing symptoms

          -  Received any investigational therapy within 30 days prior to initiation of therapy
             (Day 1 visit)

          -  Received tolvaptan 30 days prior to initiation of therapy (Day 1 visit)

          -  Received active treatment for urinary tract infection 4 weeks prior to initiation of
             therapy (Day 1 visit)

          -  History of pancreatitis or known risk of pancreatitis

          -  The subject meets any of the following cardiac criteria:

          -  Mean QTc interval corrected for heart rate using Fridericia's formula (QTcF) of &gt; 450
             msec

          -  History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic
             sinus bradycardia (&lt; 50 bpm), heart block (excluding first-degree block, being PR
             interval prolongation only), congenital long QT syndrome or new ST segment elevation
             or depression or new Q wave on ECG.

          -  Subjects with a history of atrial arrhythmias should be discussed with the Medical
             Monitor

          -  Family history of congenital long QT syndrome or unexplained cardiac death

          -  Symptomatic heart failure (per New York Heart Association guidelines), unstable
             angina, myocardial infarction, or cerebrovascular accident within 6 months prior to
             study entry

          -  History of ventricular rhythm disturbances

          -  History of cardiac arrhythmias, stroke, or myocardial infarction

          -  Has a cardiac pacemaker

          -  History of pericardial effusion or presence of pericardial effusion on screening
             echocardiogram

          -  Taking any medication known to inhibit the cytochrome P450 (CYP)3A4 isozyme or any
             drugs that are CYP3A4 inducers, or any drugs associated with torsade de pointes or
             known to prolong the QTcF interval, including anti-arrhythmic medications within 2
             weeks prior to screening

          -  Uncontrolled intercurrent illness that would limit compliance with study requirements

          -  Subject is pregnant, plans to become pregnant, or nursing

          -  HIV positive

          -  Hepatitis B or C positive

          -  Immunocompromised

          -  Documented renal vascular disease resulting in uncontrolled hypertension

          -  Previously received an epithelial growth factor receptor (EGFR)

          -  Allergy or hypersensitivity to components of tesevatinib or placebo or their
             formulations

          -  Being aphakic due to previous cataract surgery or congenital abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Associate Director of Clinical Operations</last_name>
    <phone>724-778-6125</phone>
    <email>KD019-211@kadmon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Institute for Renal Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irish Lardizaball</last_name>
      <phone>619-461-3894</phone>
      <email>ilardizabal@cairr.com</email>
    </contact>
    <investigator>
      <last_name>George Fadda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farid Arman</last_name>
      <phone>310-825-7919</phone>
      <email>PKD@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salpi Siyahian</last_name>
      <phone>415-502-3618</phone>
      <email>Salpi.Siyahian@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Meyeon Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Farmer</last_name>
      <phone>303-724-7790</phone>
      <email>beverly.farmer@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Michel Chonchol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Nephrology Clinical Research</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Blount</last_name>
      <phone>203-737-1575</phone>
      <email>katrina.blount@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Nephrology Associates Research Center, LLC</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Jackman</last_name>
      <phone>941-258-3556</phone>
      <email>bjack302@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Squires</last_name>
      <phone>941-258-3556</phone>
      <email>squires.heather.vmr@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kianoosh Kaveh, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Miller</last_name>
      <phone>813-873-1016</phone>
      <email>cassiemiller@genesisclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zohreh Forghani</last_name>
      <phone>404-712-1162</phone>
      <email>zohreh.forghani@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Frederic Rahbari-Oskoui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Lambert</last_name>
      <phone>773-834-7480</phone>
      <email>blambert@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Bharathi Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlett Diggs</last_name>
      <phone>410-328-0207</phone>
      <email>cdiggs@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Seliger, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Tucker</last_name>
      <phone>617-636-7914</phone>
      <email>ctucker@tuftsmedicalcenter.org</email>
    </contact>
    <contact_backup>
      <last_name>Peggy Healy</last_name>
      <phone>617-636-8117</phone>
      <email>mhealy2@tuftsmedicalcenter.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Perrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaelah Huntington</last_name>
      <phone>617-667-0317</phone>
      <email>shunting@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore I. Steinman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Bungum</last_name>
      <phone>507-266-4616</phone>
      <email>bungum.lisa2@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Lauber</last_name>
      <phone>314-747-3879</phone>
      <email>jlauber@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Seth Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie L Donahue, NP</last_name>
      <phone>212-746-1495</phone>
      <email>sld9001@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Irina Barash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbra Grier</last_name>
      <phone>215-615-4938</phone>
      <email>Debbra.Grier@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Sauls, BS</last_name>
      <phone>254-935-5838</phone>
      <email>Ashley.Kossie@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Johnson</last_name>
      <phone>434-924-1979</phone>
      <email>sfj8n@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Schwarz</last_name>
      <phone>414-805-7208</phone>
      <email>aschwarz@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Ashraf El-Meanawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <keyword>Polycystic Kidney</keyword>
  <keyword>Tesevatinib</keyword>
  <keyword>Polycystic Kidney Disease</keyword>
  <keyword>PKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

